Certain Celgene products are available exclusively through a select network of pharmacies due to restricted distribution programs. Your Celgene Patient Support® Specialist can provide information on which pharmacy is in-network with each patient’s insurer.
You can access the REMS Pharmacy Network List online at www.celgene.com/patients/rems-pharmacy-network.
To avoid embryo-fetal exposure, Risk Evaluation and Mitigation Strategy (REMS) programs are mandatory for the Celgene products REVLIMID® (lenalidomide), and POMALYST®(pomalidomide). The REVLIMID REMS® program, and POMALYST REMS®program require prescribers and pharmacists to be certified and patients to enroll and comply with all of the requirements for each program.
To enroll yourself and your patients, to receive more information, or to download forms related to the REMS programs, please visit www.CelgeneRiskManagement.com or call 1-888-423-5436.
REVLIMID® (lenalidomide) and POMALYST® (pomalidomide) are only available through restricted distribution programs.
Please see full Prescribing Information, including Boxed WARNINGS, for REVLIMID®, POMALYST®, IDHIFA® (enasidenib), and ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound).
Your Specialist is assigned based on the zip code of your office. To meet your Specialist, enter your zip code below.
This website is intended for
US healthcare professionals only
The ICD-10-CM Codes provided here are for diagnoses reasonably related to an indication or indications within the product’s approved label and are provided for your reference only. Other codes may be appropriate. Celgene makes no representation that any code is appropriate for a particular patient. Healthcare Professionals must use their independent judgment in selecting Code(s) to accurately reflect the diagnosis of the specific patient.